HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Efficacy and safety of tirofiban in high-risk patients with non-ST-segment elevation acute coronary syndromes.

AbstractOBJECTIVE:
To evaluate the safety and efficacy of tirofiban in high risk patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS) after percutaneous coronary intervention (PCI).
METHODS:
A total of 240 patients were randomized to either a tirofiban group or a control group.
RESULTS:
Compared with the control group, the platelet aggregation rate in the tirofiban group was lower (P < 0.01); the plasma levels of CK-MB and troponin I, cardiac form (cTnI) were lower (P < 0.05); ECG improved significantly (P < 0.05); the incidence of major adverse cardiac events (MACE) was lower (P < 0.05); and there was no difference in bleeding complications between the 2 groups (P = 0.1).
CONCLUSIONS:
The administration of tirofiban in high risk patients with NSTE-ACS after PCI is safe and effective.
AuthorsZhenxian Yan, Yujie Zhou, Yingxin Zhao, Yueping Li, Xiaomin Nie, Zhiming Zhou, Dean Jia
JournalClinical cardiology (Clin Cardiol) Vol. 32 Issue 9 Pg. E40-4 (Sep 2009) ISSN: 1932-8737 [Electronic] United States
PMID19645039 (Publication Type: Journal Article, Randomized Controlled Trial)
CopyrightCopyright 2009 Wiley Periodicals, Inc.
Chemical References
  • Biomarkers
  • Platelet Aggregation Inhibitors
  • Troponin I
  • Tyrosine
  • Creatine Kinase, MB Form
  • Tirofiban
Topics
  • Acute Coronary Syndrome (drug therapy, mortality, therapy)
  • Aged
  • Angioplasty, Balloon, Coronary (adverse effects, mortality)
  • Biomarkers (blood)
  • Creatine Kinase, MB Form (blood)
  • Double-Blind Method
  • Electrocardiography
  • Female
  • Heart Diseases (blood, etiology, mortality, prevention & control)
  • Hemorrhage (chemically induced)
  • Humans
  • Male
  • Middle Aged
  • Platelet Aggregation (drug effects)
  • Platelet Aggregation Inhibitors (adverse effects, therapeutic use)
  • Prospective Studies
  • Risk Assessment
  • Thrombocytopenia (chemically induced)
  • Time Factors
  • Tirofiban
  • Treatment Outcome
  • Troponin I (blood)
  • Tyrosine (adverse effects, analogs & derivatives, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: